Ortataxel Completed Phase 2 Trials for Metastatic Breast Cancer / Neoplasms, Breast Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00044525Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients